What Day Zero Diagnostics does

Day Zero Diagnostics is a Boston-based infectious disease diagnostics company founded in 2016 that combines whole genome sequencing with machine learning to identify bacterial and fungal pathogens and predict antimicrobial susceptibility directly from patient samples. The company's core offering is a rapid diagnostic system designed to deliver pathogen identification and antibiotic resistance profiles within approximately 8 hours, compared to multiple days for conventional culture-based methods, addressing a critical bottleneck in the treatment of serious infections and the global antimicrobial resistance crisis. Supporting products include the proprietary Blood2Bac™ sample preparation protocol for extracting microbial DNA from blood, and the epiXact® FMT pharmacovigilance assay for detecting pathogens in fecal microbiota transplant samples used in clinical trials and infection control.

The company's technology stack pairs a novel wet-lab sample preparation method with AI-driven analysis of sequencing data, and is being developed for hospital healthcare systems treating patients with suspected bloodstream infections and antimicrobial-resistant pathogens. As of September 2023, Day Zero Diagnostics had raised over $49 million in venture capital plus more than $18 million in non-dilutive funding (CARB-X and NIH), with strategic investors including BD, Sands Capital, Panacea Venture, and Hongkou Capital. The company employs 51–100 people, is privately held, and operates from a single headquarters location in Massachusetts.

The business model is currently pre-commercial: no revenue, pricing, or named customers are publicly disclosed, and the lead Rapid Diagnostic System is still in development toward FDA clearance. Capital raised to date is being deployed to improve the Blood2Bac™ protocol, accelerate the diagnostic system prototype, and fund the epiXact® FMT assay. GTM motion and revenue mechanics are not yet defined in publicly available sources, though the strategic investment from BD signals an eventual go-to-market path likely routed through hospital and clinical laboratory channels serving patients with serious infections.

Name

Day Zero Diagnostics

Website

https://dayzerodiagnostics.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

Day Zero Diagnostics is a Boston-based infectious disease diagnostics company developing genome sequencing and AI-powered systems to identify pathogens and predict antimicrobial resistance within 8 hours for hospitalized patients with serious infections.

Ownership category

akta.pro rank

Product category

Infectious Disease Diagnostics

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Point-of-Care (POC) & Rapid Diagnostics (near-patient, lateral flow) (HLAAALAG)

akta.pro secondary industries

Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD), Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA), General Infectious Disease (HLAKAGAA)

Keywords

• Infectious disease diagnostics
• Antimicrobial resistance testing
• Genomic pathogen identification
• Rapid blood culture diagnostics
• Clinical laboratory services

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Core offering

Day Zero Diagnostics is an infectious disease diagnostics company that combines whole-genome sequencing with artificial intelligence and machine learning to identify bacterial pathogens and predict antimicrobial resistance profiles directly from clinical patient samples. Its Blood2Bac™ sample preparation protocol and Rapid Diagnostic System aim to deliver species-level identification and antibiotic susceptibility information in approximately 8 hours, materially faster than traditional culture-based workflows that can take several days.

Product overview

Day Zero Diagnostics is developing a suite of genome sequencing-based diagnostic products centered around rapid pathogen identification and antimicrobial susceptibility testing. The core offering is a diagnostic system that uses whole genome sequencing combined with machine learning to identify bacterial and fungal pathogens and predict antibiotic resistance within 8 hours. Supporting products include the Blood2Bac™ sample preparation protocol for concentrating microbial DNA from blood, and the epiXact® FMT assay for fecal microbiota transplant safety monitoring. The company targets healthcare facilities dealing with infectious diseases and antimicrobial resistance.

Differentiator

Problem solved

Functional benefit

Brands

• epiXact FMT: Pharmacovigilance assay for fecal microbiota transplant safety using high-resolution genomic analysis pipeline to detect pathogens in complex samples
• Blood2Bac

Products and services

• Blood2Bac™ Sample Preparation Protocol A proprietary sample preparation protocol that processes positive blood cultures to enable downstream whole-genome sequencing and machine-learning-based pathogen identification and antimicrobial resistance prediction for hospital clinical laboratories.
• Rapid Diagnostic System An integrated diagnostic platform combining proprietary sample preparation, whole-genome sequencing, and AI/machine-learning interpretation to deliver species identification and antimicrobial resistance profiles for bloodstream infections, designed for hospital healthcare systems and clinical laboratories.
• epiXact® FMT Pharmacovigilance Assay A pharmacovigilance assay service that uses the company's sequencing and bioinformatics capabilities to support safety and quality monitoring for fecal microbiota transplantation programs.

Quantifiable outcome

• Pathogen and resistance profile identification within 8 hours, significantly faster than traditional methods
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• T2 Biosystems: T2 Biosystems develops rapid molecular diagnostics for sepsis and bloodstream infections directly from whole blood, targeting the same clinical use case (early pathogen ID) that Day Zero's sequencing-based system is designed to address.
• Accelerate Diagnostics: Accelerate Diagnostics offers rapid pathogen identification and antimicrobial susceptibility testing directly from positive blood cultures, competing head-to-head with Day Zero's 8-hour ID/AST value proposition for hospitalized infection cases.
• bioMérieux BioFire Diagnostics: BioFire's syndromic FilmArray panels (including the Blood Culture Identification panel) deliver same-day pathogen ID from positive blood cultures, making it the most direct commercial substitute for Day Zero's rapid ID/AST test.

Broad incumbents

• bioMérieux: Global microbiology leader with BIOFIRE Blood Culture Identification panels, VITEK MS, and broad hospital diagnostics — overlapping directly with Day Zero's ID/AST workflow in clinical microbiology.
• Becton, Dickinson and Company (BD): Major diagnostics and medical technology incumbent with BD MAX molecular systems and a broad microbiology portfolio; also a strategic investor in Day Zero, illustrating the overlap in target customers and applications.
• Cepheid (Danaher): Cepheid's GeneXpert platform is a dominant rapid molecular diagnostics system in hospitals, with sepsis and infection-related cartridges that compete for the same clinical decision points Day Zero targets.
• QIAGEN: QIAGEN provides sample-prep technologies and molecular diagnostic assays for infectious disease, overlapping with Day Zero's Blood2Bac™ sample-prep innovation and PCR-based ID workflows used in hospital labs.
• Hologic: Hologic's Panther / Panther Fusion systems and broad women's health and infectious disease molecular menu compete in the hospital molecular diagnostics space Day Zero is targeting.
• Roche Diagnostics: Roche offers cobas molecular systems and a broad infectious disease and sepsis test menu in hospital labs, representing a large incumbent competitor in the same clinical workflow Day Zero aims to disrupt.

Emerging players

• Illumina: Illumina is the dominant DNA sequencing platform provider and has been expanding into clinical infectious disease applications, making it both a potential technology supplier and adjacent emerging competitor to Day Zero's sequencing-based diagnostic approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds13 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Day Zero Diagnostics